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This study sought to determine the diagnostic utility of perfusion parameters derived from dynamic contrast-enhanced
(DCE) perfusion MRI with a short acquisition time (approximately 3.5 min) in patients with glioma, brain metastasis, and
primary CNS lymphoma (PCNSL).
Twenty-six patients with 29 lesions (4 low-grade glioma, 13 high-grade glioma, 7 metastasis, and 5 PCNSL) underwent
DCE-MRI in a 3 T scanner. A ROI was placed on the hotspot of each tumor in maps for volume transfer contrast Ktrans,
extravascular extracellular volume Ve, and fractional plasma volume Vp. We analyzed differences in parameters between
tumors using the Mann–Whitney U test. We calculated sensitivity and specificity using receiver operating characteristics
analysis.
Mean K trans values of LGG, HGG, metastasis and PCNSL were 0.034, 0.31, 0.38, 0.44, respectively. Mean Ve values of
each tumors was 0.036, 0.57, 0.47, 0.96, and mean Vp value of each tumors was 0.070, 0.086, 0.26, 0.17, respectively.
Compared with other tumor types, low-grade glioma showed lower Ktrans (P < 0.01, sensitivity = 88%, specificity = 100%)
and lower Ve (P < 0.01, sensitivity = 96%, specificity = 100%). PCNSL showed higher Ve (P < 0.01, sensitivity = 100%,
specificity = 88%), but the other perfusion parameters overlapped with those of different histology.
Kinetic parameters derived from DCE-MRI with short acquisition time provide useful information for the
differential diagnosis of brain tumors.
Keywords: Magnetic resonance imaging (MRI); Dynamic contrast enhanced (DCE) perfusion; Brain tumor;
Two-compartment model analysis; Pharmacokinetic model analysisIntroduction
The differential diagnosis of brain tumor is critical to de-
termining optimal therapy and estimating prognosis
(DeAngelis 2001). High grade glioma, brain metastasis,
and primary central nervous system lymphoma (PCNSL)
are common types of brain malignancies in adults and can
sometimes present similar results on conventional MR im-
aging (Ma et al. 2010). Dynamic contrast-enhanced (DCE)
imaging, which allows for noninvasive evaluation of tumor
vascularity, has been widely used to assess the physiology
of brain tumor vascularity (Tofts 1996; Tofts et al. 1999).* Correspondence: abe.takashi@tokushima-u.ac.jp
1Department of Radiology, Institute of Health Biosciences, The University of
Tokushima Graduate School, 3-18-15, Kuramoto-cho, Tokushima City,
Tokushima 770-8509, Japan
Full list of author information is available at the end of the article
© 2015 Abe et al.; licensee Springer. This is an
Attribution License (http://creativecommons.or
in any medium, provided the original work is pDynamic acquisition of images during contrast en-
hancement allows for the specific descriptive parame-
ters related to local microvasculature characteristics to
be calculated. Both relaxivity (T1)- and susceptibility
(T2*)-based approaches have demonstrated good poten-
tial for measuring the characteristics of tumor vasculature
(Quarles et al. 2012). Methods to assess changes in tissue
T1 following contrast agent injection are commonly
termed DCE-MRI and have been widely performed to
assess microvascular permeability (Tofts 1996; Tofts et al.
1999). In DCE-MRI, the signal intensity change can be
measured with sufficient temporal resolution and is
related to tissue contrast agent concentration.
The pharmacokinetic (PK) model introduced by Tofts
et al. can also be used to calculate volume transfer contrast
Ktrans, volume of extravascular extracellular space Ve, andOpen Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.






LGG 4 (1) 53.3 (35–77) 3 oligodendrogliomas, 1
diffuse astrocytoma
HGG 13 (9) 59.2 (34–84) 1 anaplastic astrocytoma, 1
anaplastic oligodendroglioma,
1 gliosarcoma, 8 glioblastomas,
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As such, DCE-MRI can provide information on the blood
microcirculation of tumors that cannot be acquired from
conventional MRI (Tofts 1996; Tofts et al. 1999; Patankar
et al. 2005; Xyda et al. 2012; Sorensen et al. 2009; Bisdas
et al. 2011; Mills et al. 2006). In the brain, previous studies
have used these kinetic parameters to evaluate glioma
grade (Patankar et al. 2005), differential diagnosis (Xyda
et al. 2012), treatment effects in primary brain tumors
(Sorensen et al. 2009), diagnosing recurrence from radi-
ation injury (Bisdas et al. 2011) and predicting prognosis
(Mills et al. 2006).
DCE data measured with sufficient temporal reso-
lution and acquisition time can provide useful results in
PK model analysis (Tofts 1996; Larsson et al. 2013). Ac-
quisition times of over 5 min have been used for the
diagnosis of brain tumors in recent years (Bisdas et al.
2011; Aref et al. 2008; Awasthi et al. 2012; Bagher-
Ebadian et al. 2012; Jia et al. 2012) and are recom-
mended to maintain reliability (Larsson et al. 2013).
But due to practical time limitations for an MRI exam-
ination, a DCE sequence with a short acquisition time
and high diagnostic performance is required. Although
DCE sequences with short acquisition times result in
overestimated Ktrans and underestimated Ve and Vp, the
resultant error is not so large at acquisition times of 3–
4 min. Further, when using the same DCE protocol for
different tumor types, parametric errors occur in the
same direction, so their resulting distributions could be
unchanged and diagnostic utility is preserved. In fact,
there have been investigations on brain, head and neck,
and breast neoplasms using DCE sequences of less than
5 min and the Tofts model (Awasthi et al. 2012; El
Khouli et al. 2011; Shukla-Dave et al. 2012). Addition-
ally, for use in clinical practice, reduced operation time
is important and can be achieved with automated post-
processing and fixed T1 method (Haacke et al. 2007),
which uses preselected T1 value as a precontrast T1
value (T10) of the target organ to reduce the noise de-
rived from T1 map and to reduce total acquisition
time.
Against this background, the main purpose of this
study was to investigate the diagnostic utility of DCE-
MRI in diagnosing glioma, metastasis, and PCNSL
tumors using a relatively short acquisition time and to re-
duce operation time using automated post-processing and
a fixed T1 method.2 recurrent high grade glioma
Metastasis 6 (4) 64.3 (48–77) 2 lung cancers*, 2 breast




3 (3) 69.0 (55–78) 3 diffuse large B-cell
lymphomas
*:Three cases were diagnosed clinically (1 lung cancer, 1 breast cancer and
colon cancer). The others were diagnosed pathologically.Materials and methods
This study was approved by the university hospital of
Tokushima clinical trial center for developmental thera-
peutics, and informed consent was obtained from all
patients prior to enrollment.Patients
Fifty-two consecutive patients who underwent contrast-
enhanced MRI for diagnosing suspected brain tumor be-
tween December 2012 and December 2013 were eligible
for this study. From this group, those with glioma, metasta-
sis, and PCNSL were included in the analysis. Diagnosis
was made histologically or clinicoradiologically. Clinicora-
diological diagnosis was made by consensus of two experi-
enced neuroradiologists. Metastases were defined as newly
emerging nodules in cancer patients; and recurrence of gli-
oma were defined as a steady increase in contrast enhanced
T1-weighted images. MRI follow-up was performed at
2-month intervals or sooner. Twenty-six patients (17 men
and 9 women; mean age 61 years, age range 35–84,years;
29 lesions) were included in the analysis. The time from
examination to diagnosis was recorded. We divided
tumors into four groups: low grade glioma (LGG), high
grade glioma (HGG), metastasis, and PCNSL. Table 1
summarizes the patient information.
Imaging protocol
Examinations were performed with a 3 T MR scanner
(Discovery 750, GE Healthcare, Milwaukee, WI) using
a standard eight-channel head coil. Pre-contrast T1-
weighted images, T2-weighted images, diffusion-weighted
images, arterial spin labeling images, and MR spectros-
copy were acquired. Subsequently, DCE-MRI and post-
contrast T1-weighted images were acquired with contrast
agent (Gd-DTPA, 0.1 mmol/kg; Magnevist, Bayer Health-
Care, Berlin, Germany). We performed 3D T2*-weighted
angiography and DTI in selected patients.
DCE-MRI was acquired using a 3D fast spoiled gradi-
ent echo sequence with TR = 4.4 ms, TE = 1 ms, flip
angle = 12°, field of view = 300 × 210 mm, matrix = 128 ×
90, slice thickness = 8 mm, and number of slices = 16,
consisting of 64 phases with a temporal spacing of 3.3 s.
We chose TR, TE, and flip angle in accordance with
those of an ordinary spoiled gradient echo sequence.
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contrast agent was injected with a power injector
(Medrad, Indianola, PA) at a rate of 2.5 ml/s after two
cycles of dynamic scan. Immediately afterward, 20 ml of
saline was injected at the same rate.
Image analysis
All imaging data were transferred from the scanner to a
workstation (Advantage Workstation 4.6, GE Medical
Systems, Milwaukee, WI). We analyzed DCE data using
the Tofts model implemented in the commercially avail-
able software GenIQ (GE Medical Systems, Milwaukee,
WI). We used 3-dimensional, rigid motion correction,
which conduct a combination of rotational movement
and translation in all cases. Referring to the temporal
changes of the signal intensity of all voxel, the software
automatically extracts the pixels that considered to ar-
teries and veins. In the analysis, we used fixed T1
method (Haacke et al. 2007) and default T10 value
(T10 = 1000 ms).
Data analysis
We selected enhanced lesions with a minor axis of more
than twice the slice thickness (16 mm) and include them
in the following analysis. In each map, we set an ROI of
approximately 100 mm2 at the hot spot of the tumor.
We measured average Ktrans, Ve, and Vp in each tumor.
We then assessed the correlation of PK model parame-
ters with different parametric maps and tumor histology.
Statistical analysis
We first calculated correlations between the DCE parame-
ters Ktrans, Ve, and Vp using Spearman’s rank correlation
coefficient. We then assessed the correlation between
DCE parameters and tumor histology. Results are
expressed as mean ± standard deviation. Statistical differ-
ence between tumors was determined using the Mann–
Whitney U test. A P value of less than 0.05 was considered
statistically significant.
Finally, we assessed the utility of Ktrans, Ve, and Vp in
diagnosis of the brain tumors. From the results of this
analysis, we selected a group of tumors with distinct PK
parameters. We performed receiver operating characteris-
tics (ROC) curve analysis for selected tumors to evaluate
the optimal cutoff value, sensitivity, and specificity.
All statistical analysis was performed using Excel
Statistics 2012 (Social Survey Research Information Co.,
Ltd., Tokyo, Japan) with Excel 2010 (Microsoft Co.,
Redmond, WA).
Results
The time from examination to diagnosis was 5 days (3 and
12 days: 25th and 75th percentiles). Data transfer and
post-processing took approximately 10–12 min.Contrast-enhanced T1-weighted imaging for a repre-
sentative glioblastoma case (Figure 1) showed increased
Ktrans,Ve, and Vp. There was an intermediate correlation
between Ktrans and Ve (R
2 = 0.41), while Vp showed rela-
tively weak correlations with Ktrans and Ve (R
2 = 0.17 and
0.18, respectively)
LGG showed lower Ktrans and Ve than the other malig-
nant tumor types (P < 0.01). Among the other tumor
types, Ktrans values overlapped. Lymphoma showed ex-
tremely high Ve (P < 0.01), but Ve for HGG and metastasis
overlapped. No statistical differences were found for Vp
(Figure 2).
Area under the ROC curve for differentiating LGG
and PCNSL was highest for Ve (LGG: 0.97, PCNSL:
0.95). A cutoff value of Ktrans = 0.0848 for diagnosis of
LGG provided the best good combination of sensitivity
and specificity (0.88 and 1.0, respectively). A cutoff value
of Ve = 0.18 for diagnosis of LGG provided the best good
combination of sensitivity and specificity (0.96 and 1.0,
respectively). A cutoff value of Ve = 0.912 for diagnosis
of PCNSL provided the best combination of sensitivity
and specificity (1.00 and 0.88, respectively).
Discussion
The results of this study indicate that kinetic parameters
acquired from DCE perfusion study with short acquisi-
tion time supplement conventional imaging in predict-
ing tumor histology. This method takes only about
15 min (scan time of 3.5 min plus post-processing time
of 10–12 min) and is not subject to operator-dependent
bias, making it highly feasible in clinical settings.
Ktrans and Ve demonstrated modest correlation with
each other. Ve was the most useful parameter in diag-
nosing LGG and PCNSL, while Ktrans was effective in
differentiating LGG from the other tumors. Vp failed to
prove useful in differentiating brain tumor types in this
study group.
Although the utility of the two-compartment PK
model methods in brain tumor diagnosis has been re-
ported (Patankar et al. 2005; Xyda et al. 2012; Sorensen
et al. 2009; Bisdas et al. 2011; Aref et al. 2008; Awasthi
et al. 2012; Bagher-Ebadian et al. 2012; Jia et al. 2012), it
has not extended to clinical practice. One of the reasons
for this is the long acquisition time. In the present study,
we confirmed that the diagnostic performance of DCE
analysis using a short acquisition time is comparable to
that of methods in previous studies. We believe, there-
fore, that this method provides new and useful perform-
ance improvements for tumor diagnosis.
Another method, first-pass pharmacokinetic model
(FPPM) analysis, can be performed from DCE analysis
data with an ultra-short acquisition time of about 1 min
(Li et al. 2000). Ktrans and Vp can also be calculated with
this method and are comparable to the data obtained
Figure 1 Magnetic resonance imaging of a glioblastoma. A, Axial post-contrast T1-weighted image shows a ringed enhanced lesion in the
left thalamus and subtle enhancement in the right thalamus. B, C, and D, Three kinetic parametric maps show increased vascular permeability
(B; Ktrans map), leakage space (C; Ve map), and plasma volume (D; Vp map) corresponding to the enhanced area on the contrast-enhanced MRI.
Figure 2 Scatter plot (mean ± standard deviation) shows 3 kinetic parameters for 4 brain tumor types. A: Ktrans, B: Ve, C: Vp. LGG: low grade
glioma, HGG: high grade glioma, PCNSL: primary CNS lymphoma, *: significant difference (P < 0.05, Mann–Whitney U test) between tumor groups.
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2004). Since, in the FPPM method, tracer concentration
in arterial blood plasma is assumed to be much larger
than that in the extravascular extracellular component,
Ve cannot be calculated (Li et al. 2000). Although con-
ventional PK model analysis requires a longer acquisi-
tion time than the FPPM method, we believe the utility
of Ve in the diagnosis of brain tumors justifies the longer
acquisition time of conventional PK model analysis.
Permeability indices, including Ktrans, have been shown
in a number of earlier studies to correlate with glioma
grade and to overlap between HGG, metastasis and
Lymphoma (Xyda et al. 2012; Awasthi et al. 2012; Zhang
et al. 2012; Johnson et al. 2004). Our findings are consist-
ent with these previous studies. Since, the noninvasive es-
timation of vascular permeability using DCE-perfusion
analysis can be useful not only for the diagnosis of the
brain tumor (Xyda et al. 2012) but also the malignant po-
tential of the tumor (Patankar et al. 2005), response to bio-
logical therapy (Checkley et al. 2003; Keunen et al. 2011),
and prognosis (Mills et al. 2006), DCE perfusion imaging
with a short acquisition time would contribute greatly to
various clinical situations.
Previous studies have revealed that Ve correlates with
glioma grade (Awasthi et al. 2012; Zhang et al. 2012),
and Ve of lymphoma was higher than that of HGG
(Johnson et al. 2004). The present results are in agree-
ment with these previous studies, with Ve showing the
highest sensitivity and specificity in the diagnosis of
LGG and PCNSL.
The physiological meaning of Ve is still unclear. Ve
has been defined as “leakage space” in an initial study
(Tofts 1996) and as extravascular extracellular space or
its volume in later studies (Tofts et al. 1999). Aref et al. and
Aryal et al. reported that interstitial volume fraction mea-
sured by DCE-MRI correlated with histologically measured
extracellular space fraction in mammary tumor(Aref et al.
2008) and cerebral glioma models (Aryal et al. 2014) in rats.
However, Mills et al. and Arlinghaus et al. reported that Ve
did not correlate with apparent diffusion coefficient in pa-
tients with brain glioblastoma (Mills et al. 2010) and breast
cancer (Arlinghaus et al. 2011). Since apparent diffusion
coefficient inversely correlates with tumor cellularity
(Guo et al. 2002), these results are thought to contra-
dict the correlation between Ve and cellularity.
Additionally, Ve was very high in lymphoma in the
present study, which indicates large extravascular extra-
cellular space fraction and low tumor cell density. How-
ever, PCNSL is generally a tumor with a high degree of
cellularity (Guo et al. 2002). This indicates Ve provides
independent information about the tumor microenvir-
onment. Further investigation involving radiological-
pathological correlation is needed to reveal the true
physiological meaning of Ve.In this study, Vp did not contribute to the diagnosis of
the brain tumors, which is somewhat surprising because
new blood vessel proliferation in malignant tumors results
in increased vascular density. We hypothesized that the Vp
of malignant tumors (i.e., HGG, metastasis, and PCNSL)
would be higher than LGG, but there was no statistical
difference. This preliminary study included a small num-
ber of patients and thus statistical power to detect such
difference was weak. Further study is needed to determine
the meaning of Vp in the diagnosis of brain tumors.
There were other limitations in addition to the small
number of patients sampled. We used a DCE-MRI se-
quence with a short acquisition time and could not com-
pare our results with those from a longer acquisition time.
Therefore, we could not evaluate precision of the kinetic
parameters themselves. Another limitation was the exist-
ence of post-processing software-dependent bias. Kinetic
parameters vary between post-processing software (Heye
et al. 2013), and our results may have differed if we were
to use different software. Finally, the DCE sequence pa-
rameters, fixed T1 method, contrast agent, and injection
rate also influenced the results. If we were to perform the
same experiment with different settings, the results should
show the same tendency as in the present study but the
kinetic parameters would be different.
In conclusion, we demonstrated the utility of DCE-MRI
with a short acquisition time in the differential diagnosis of
brain tumors. Operation time was also reduced using auto-
matic vascular function detection and a fixed T1 method.
With shortened times for image acquisition, analysis, and
operation, the described method shows high feasibility for
clinical use.
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